| Date Filed | Type | Description |
| 06/13/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/09/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 06/09/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 06/08/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/08/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/03/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 06/03/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 06/02/2022 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 06/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/27/2022 |
SC 13D/A
| New Enterprise Associates 16, L.P. has filed a Schedule 13D for Genocea Biosciences, Inc. |
| 05/24/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/28/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs... |
| 03/18/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/18/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/16/2022 |
5
| Flechtner Jessica Baker (Chief Scientific Officer) has filed a Form 5 on GENOCEA BIOSCIENCES, INC. |
| 03/16/2022 |
5
| Duvall Diantha (CFO) has filed a Form 5 on GENOCEA BIOSCIENCES, INC. |
| 03/16/2022 |
5
| Davis Thomas Andrew (CHIEF MEDICAL OFFICER) has filed a Form 5 on GENOCEA BIOSCIENCES, INC. |
| 03/16/2022 |
5
| Clark William D (President and CEO) has filed a Form 5 on GENOCEA BIOSCIENCES, INC. |
| 03/16/2022 |
5
| Aakalu Girish N (CHIEF BUSINESS OFFICER) has filed a Form 5 on GENOCEA BIOSCIENCES, INC. |
| 03/10/2022 |
8-K
| Quarterly results |
| 03/07/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 5.4% stake in Genocea Biosciences, Inc. |
| 02/14/2022 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 6.2% stake in Genocea Biosciences Inc |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2022 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 9.9% stake in Genocea Biosciences, Inc. |
| 01/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 10/28/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/28/2021 |
8-K
| Quarterly results |
| 09/13/2021 |
8-K
| Quarterly results |
| 07/29/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/29/2021 |
8-K
| Quarterly results |
|